The severe to very severe chronic obstructive pulmonary disease (COPD) drug market is becoming increasingly crowded as several LAMAs, LABA/ICSs, LABA/LAMAs, and, most recently, LABA/LAMA/ICSs compete for a share of the maintenance space. Unfortunately, none of these agents can reverse the disease’s progression or repair lung tissue; instead, these treatments focus on improving breathing and reducing inflammation. Although inhaled medications are effective in reducing the burden of COPD by easing its symptoms, patients’ quality of life still suffers, and the disease remains one of the leading causes of death worldwide. Thus, significant unmet need remains for more-effective therapies, especially for those patients whose symptoms are not adequately controlled with available therapies.
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 31 European pulmonologists fielded in February 2021
Key companies: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline
Key drugs: Advair / Seretide, Anoro, Spiriva, Stiolto / Spiolto, Symbicort, Trelegy, Yupelri